Rubric Capital Management LP Acquires Shares of 293,083 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Rubric Capital Management LP bought a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 293,083 shares of the life sciences company’s stock, valued at approximately $5,325,000. Rubric Capital Management LP owned about 0.38% of Integra LifeSciences at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. CWM LLC raised its position in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the period. Blue Trust Inc. lifted its stake in Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Integra LifeSciences by 1.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock valued at $1,764,000 after purchasing an additional 551 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Integra LifeSciences by 7.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock valued at $421,000 after purchasing an additional 1,010 shares during the period. Finally, KBC Group NV increased its position in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Truist Financial lowered their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Finally, JMP Securities cut their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $24.00.

Integra LifeSciences Trading Down 2.2 %

Shares of IART stock opened at $23.70 on Wednesday. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42. The business’s fifty day moving average is $20.22 and its 200 day moving average is $24.02. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter last year, the firm posted $0.76 EPS. The company’s revenue was down .4% compared to the same quarter last year. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.